Eldelumab (BMS-936557) 是一种人源化抗CXCL10 (IP-10)单克隆抗体 (IgG1型)。Eldelumab 可选择性地与CXCL10结合，并阻断CXCL10诱导的钙通量和细胞迁移。Eldelumab 可用于自身免疫和自身炎症性疾病 (如类风湿性关节炎、溃疡性结肠炎和克罗恩病) 的研究。
| 生物活性 | Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10)monoclonal antibody (IgG1 type). Eldelumab selectively binds toCXCL10and blocksCXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease[1][2]. |
| IC50& Target | |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
